15 November 2024 - Novartis Canada is extremely disappointed that negotiations for Pluvicto (lutetium (Lu 177 ) vipivotide tetraxetan injection), a treatment for patients with progressive PSMA positive metastatic castration resistant prostate cancer, with the pan-Canadian Pharmaceutical Alliance have closed without an agreement.

This outcome is a significant setback for people living with metastatic castration resistant prostate cancer whose cancer is progressing despite standard therapies. Since the Health Canada approval of Pluvicto in September 2022, Novartis has heard from clinicians, patients, and their loved ones, about the critical unmet need for metastatic castration resistant prostate cancer patients who have exhausted all other treatment options.

Read Novartis press release